Biomedicine & Pharmacotherapy,
Journal Year:
2024,
Volume and Issue:
173, P. 116294 - 116294
Published: Feb. 23, 2024
Lung
cancer,
a
leading
global
cause
of
mortality,
poses
significant
public
health
challenge
primarily
linked
to
tobacco
use.
While
contributes
over
90%
cases,
factors
like
dietary
choices
and
radiation
exposure
also
play
role.
Despite
potential
benefits
from
early
detection,
cancer
patients
face
hurdles,
including
drug
resistance,
chemotherapy
side
effects,
high
treatment
costs,
limited
healthcare
access.
Traditional
medicinal
plant
knowledge
has
recently
unveiled
diverse
chemopreventive
agents
terrestrial
marine
sources.
These
phytochemicals
regulate
intricate
molecular
processes,
influencing
the
immune
system,
apoptosis,
cell
cycle,
proliferation,
carcinogen
elimination,
antioxidant
levels.
In
pursuing
cutting-edge
strategies
combat
forms
technological
advancements
have
spurred
innovative
approaches.
Researchers
focused
on
green
synthesis
metallic
nanoparticles
using
metabolites.
This
method
offers
distinct
advantages
conventional
physical
chemical
techniques,
such
as
cost-effectiveness,
biocompatibility,
energy
efficiency.
Metallic
nanoparticles,
through
various
pathways
generation
reactive
oxygen
species,
modulation
enzyme
activity,
DNA
fragmentation,
disruption
signaling
pathways,
perturbation
membranes,
interference
with
mitochondrial
function
resulting
in
damage,
cycle
arrest,
exhibit
for
preventive
applications.
Thus,
amalgamation
phytocompounds
holds
promise
novel
approach
lung
therapy.
However,
further
refinements
are
necessary
enhance
environmentally
friendly
process
nanoparticle
synthesis.
Drugs,
Journal Year:
2020,
Volume and Issue:
81(3), P. 317 - 331
Published: Dec. 28, 2020
The
cyclin-dependent
kinase
(CDK)
4/6
inhibitors
belong
to
a
new
class
of
drugs
that
interrupt
proliferation
malignant
cells
by
inhibiting
progression
through
the
cell
cycle.
Three
such
inhibitors,
palbociclib,
ribociclib,
and
abemaciclib
were
recently
approved
for
breast
cancer
treatment
in
various
settings
combination
regimens.
On
basis
their
impressive
efficacy,
all
three
CDK4/6
now
play
an
important
role
patients
with
HR+,
HER2-
cancer;
however,
optimal
use
still
needs
be
established.
have
many
similarities
both
pharmacokinetics
pharmacodynamics.
However,
there
are
some
differences
on
which
choice
particular
inhibitor
individual
patient
can
important.
In
this
article,
clinical
pharmacokinetic
pharmacodynamic
profiles
reviewed
future
directions
applicability
will
discussed.
Cells,
Journal Year:
2020,
Volume and Issue:
9(7), P. 1665 - 1665
Published: July 10, 2020
DNA
is
the
source
of
genetic
information,
and
preserving
its
integrity
essential
in
order
to
sustain
life.
The
genome
continuously
threatened
by
different
types
lesions,
such
as
abasic
sites,
mismatches,
interstrand
crosslinks,
or
single-stranded
double-stranded
breaks.
As
a
consequence,
cells
have
evolved
specialized
damage
response
(DDR)
mechanisms
integrity.
By
orchestrating
multilayer
signaling
cascades
specific
for
type
lesion
that
occurred,
DDR
ensures
information
preserved
overtime.
In
last
decades,
repair
been
thoroughly
investigated
untangle
these
complex
networks
pathways
processes.
result,
key
factors
identified
control
coordinate
circuits
time
space.
first
part
this
review,
we
describe
critical
processes
encompassing
sensing
resolution.
second
part,
illustrate
consequences
partial
complete
failure
machinery.
Lastly,
will
report
examples
which
knowledge
has
instrumental
develop
novel
therapies
based
on
editing
technologies,
CRISPR-Cas.
Frontiers in Oncology,
Journal Year:
2021,
Volume and Issue:
11
Published: July 12, 2021
Targeted
therapies
such
as
Cyclin
Dependent
Kinase
4
and
6
(CDK
4/6)
inhibitors
have
improved
the
prognosis
of
metastatic
hormone
receptor
(HR)
positive
breast
cancer
by
combating
resistance
seen
with
traditional
endocrine
therapy.
The
three
approved
agents
currently
in
market
are
palbociclib,
ribociclib
abemaciclib.
Besides
overall
similarities
associated
CDK4/6
inhibition,
there
differences
between
that
may
explain
noted
unique
clinical
scenarios-
monotherapy,
patients
brain
metastases
or
use
adjuvant
setting.
This
review
article
will
explore
preclinical
pharmacological
help
understand
benefits
these
certain
subgroups
HR
cancer.
Cancer Biology & Therapy,
Journal Year:
2022,
Volume and Issue:
23(1), P. 34 - 50
Published: Jan. 3, 2022
C-Myc
overexpression
is
a
common
finding
in
pancreatic
cancer
and
predicts
the
aggressive
behavior
of
cells.
It
binds
to
promoter
different
genes,
thereby
regulating
their
transcription.
downstream
KRAS
interacts
with
several
oncogenic
proliferative
pathways
cancer.
enhances
aerobic
glycolysis
cells
regulates
glutamate
biosynthesis
from
glutamine.
provides
enough
energy
for
cells'
metabolism
sufficient
substrate
synthesis
organic
molecules.
associated
chemoresistance,
intra-tumor
angiogenesis,
epithelial-mesenchymal
transition
(EMT),
metastasis
Despite
its
title,
c-Myc
not
"undruggable"
recent
studies
unveiled
that
it
can
be
targeted,
directly
or
indirectly.
Small
molecules
accelerate
ubiquitination
degradation
have
been
effective
preclinical
studies.
hinder
c-Myc-MAX
heterodimerization
c-Myc/MAX/DNA
complex
formation
functionally
inhibit
c-Myc.
In
addition,
targeted
through
transcriptional,
post-transcriptional,
translational
modifications.
Cancer Cell International,
Journal Year:
2022,
Volume and Issue:
22(1)
Published: Oct. 20, 2022
The
Cyclin-dependent
kinase
(CDK)
class
of
serine/threonine
kinases
has
crucial
roles
in
the
regulation
cell
cycle
transition
and
is
mainly
involved
pathogenesis
cancers.
expression
CDKs
controlled
by
a
complex
regulatory
network
comprised
genetic
epigenetic
mechanisms,
which
are
dysregulated
during
progression
cancer.
abnormal
activation
results
uncontrolled
cancer
proliferation
induction
stem
characteristics.
levels
can
be
utilized
to
predict
prognosis
treatment
response
patients,
further
understanding
function
underlying
mechanisms
human
tumors
would
pave
way
for
future
therapies
that
effectively
target
CDKs.
Defects
mutations
genes
coding
cell-cycle
proteins
lead
unrestrained
cells
leading
formation
tumors.
A
number
modalities
have
been
designed
combat
dysregulation
through
affecting
or
activity
However,
effective
application
these
methods
clinical
settings
requires
recognition
role
each
type
cancer,
their
partners,
interactions
with
signaling
pathways
effects
suppression
on
malignant
features.
Thus,
we
this
literature
search
summarize
findings
at
cellular
level,
as
well
vivo
levels.
Cancer Gene Therapy,
Journal Year:
2024,
Volume and Issue:
31(9), P. 1283 - 1291
Published: Feb. 26, 2024
Dysregulated
cellular
proliferation
represents
a
hallmark
feature
across
all
cancers.
Aberrant
activation
of
the
cyclin-dependent
kinase
4
and
6
(CDK4/6)
pathway,
independent
mitogenic
signaling,
engenders
uncontrolled
breast
cancer
cell
proliferation.
Consequently,
advent
CDK4/6
inhibition
has
constituted
pivotal
milestone
in
realm
targeted
therapy.
The
combination
inhibitors
(CDK4/6i)
with
endocrine
therapy
(ET)
emerged
as
foremost
therapeutic
modality
for
patients
afflicted
hormone
receptor-positive
(HR
+
)/HER2-negative
(HER2-)
advanced
cancer.
At
present,
Food
Drug
Administration
(FDA)
sanctioned
various
CDK4/6i
employment
primary
treatment
regimen
HR
/HER2-
This
approach
demonstrated
substantial
extension
progression-free
survival
(PFS),
often
amounting
to
several
months,
when
administered
alongside
Within
this
comprehensive
review,
we
systematically
evaluate
utilization
strategies
subpopulations
explore
potential
avenues
following
disease
progression
during
application
Pharmaceuticals,
Journal Year:
2024,
Volume and Issue:
17(1), P. 104 - 104
Published: Jan. 11, 2024
Pyrimidines
have
become
an
increasingly
important
core
structure
in
many
drug
molecules
over
the
past
60
years.
This
article
surveys
recent
areas
which
pyrimidines
had
a
major
impact
discovery
therapeutics,
including
anti-infectives,
anticancer,
immunology,
immuno-oncology,
neurological
disorders,
chronic
pain,
and
diabetes
mellitus.
The
presents
synthesis
of
medicinal
agents
highlights
role
biological
target
with
respect
to
disease
model.
Additionally,
potency,
ADME
properties
pharmacokinetics/pharmacodynamics
(if
available)
are
discussed.
survey
attempts
demonstrate
versatility
pyrimidine-based
drugs,
not
only
for
their
potency
affinity
but
also
improved
chemistry
pyrimidine
as
bioisostere
phenyl
other
aromatic
π
systems.
It
is
hoped
that
this
will
provide
insight
researchers
considering
scaffold
chemotype
future
candidates
order
counteract
medical
conditions
previously
deemed
untreatable.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(5), P. 901 - 901
Published: Feb. 23, 2024
Liver
cancer,
predominantly
hepatocellular
carcinoma
(HCC),
globally
ranks
sixth
in
incidence
and
third
cancer-related
deaths.
HCC
risk
factors
include
non-viral
hepatitis,
alcohol
abuse,
environmental
exposures,
genetic
factors.
No
specific
alterations
are
unequivocally
linked
to
tumorigenesis.
Current
standard
therapies
surgical
options,
systemic
chemotherapy,
kinase
inhibitors,
like
sorafenib
regorafenib.
Immunotherapy,
targeting
immune
checkpoints,
represents
a
promising
avenue.
FDA-approved
checkpoint
such
as
atezolizumab
pembrolizumab,
show
efficacy,
combination
enhance
clinical
responses.
Despite
this,
the
treatment
of
(HCC)
remains
challenge,
complex
tumor
ecosystem
immunosuppressive
microenvironment
associated
with
it
hamper
efficacy
available
therapeutic
approaches.
This
review
explores
current
advanced
approaches
treat
HCC,
considering
both
known
new
potential
targets,
especially
derived
from
proteomic
analysis,
which
is
today
considered
most
approach.
Exploring
novel
strategies,
this
discusses
antibody
drug
conjugates
(ADCs),
chimeric
antigen
receptor
T-cell
therapy
(CAR-T),
engineered
antibodies.
It
then
reports
systematic
analysis
main
ligand/receptor
pairs
molecular
pathways
reported
be
overexpressed
cells,
highlighting
their
limitations.
Finally,
TGFβ,
one
targets
microenvironment.
